Literature DB >> 30128157

Corneal abscess due to Moraxella nonliquefaciens.

Fernando Cobo1, Javier Rodríguez-Granger1, Antonio Sampedro1, José María Navarro-Marí1.   

Abstract

Entities:  

Keywords:  MALDI-TOF MS; Moraxella nonliquefaciens; corneal abscess; endophthalmitis; ocular alterations

Year:  2018        PMID: 30128157      PMCID: PMC6096928          DOI: 10.1099/jmmcr.0.005150

Source DB:  PubMed          Journal:  JMM Case Rep        ISSN: 2053-3721


× No keyword cloud information.

Case summary

A 71-year-old man was seen due to red eye along with loss of vision in the right eye. The patient only referred to a whitish spot on the corneal surface over 3 months probably due to a strange body, but no antimicrobial treatment was started at this stage. Physical examination revealed a central corneal infiltrate in almost all the corneal thickness, an overlying epithelial defect, and a moderate corneal oedema without hypopyon. Several corneal biopsies were taken, and they were directly inoculated to aerobic blood agar (Columbia Agar 5 % Sheepblood, Becton Dickinson), chocolate agar (Choco Agar, Becton Dickinson), Sabouraud agar (Sabouraud Glucose Agar, Becton Dickinson) and thioglycolate broth (Fluid Thioglycollate Medium, Becton Dickinson). All media were incubated at 37  °C, except Sabouraud agar, which was incubated at 30 °C. A corneal biopsy for study of viruses was also taken, being negative for adenovirus, herpes simplex (1 and 2) and enterovirus (by polymerase chain reaction). Gram staining of the fluid identified scarce Gram-negative rods. On the first day of incubation the growth of abundant colonies of a non-haemolytic and catalase- and oxidase-positive microorganism was reported in pure culture. No other microorganisms were isolated on the primary plates. A mass spectrometry method (Biotyper, Bruker) was employed to identify the strain as Moraxella nonliquefaciens (log score 2.08). The culture in Sabouraud agar was negative after 21 days of incubation. The MIC of the bacteria to different antibiotics was determined by the E-test method. Until now, no breakpoints have been established for species of Moraxella other than Moraxella catarrhalis. Taking into account the 2018 EUCAST breakpoints for M. catarrhalis [1], the strain was susceptible to all antimicrobials tested, except for amoxicillin (β-lactamase-positive). The MICs were as follows: amoxicillin– clavulanate (0.032 µg ml−1), cefotaxime (0.047 µg ml−1), levofloxacin (0.06 µg ml−1), azythromycin (0.047 µg ml−1), thrimetroprim–sulphametoxazole (0.19 µg ml−1), and amoxicillin (12 µg ml−1). Treatment was started with vancomycin plus ceftazidime plus cycloplegic eyedrops, along with tobramycin in ointment. Later, vancomycin was stopped and treatment was changed to azythromycin plus ceftazidime eyedrops. The patient responded favourably with slow re-epithelization of the cornea.

Question

What is the main cause of endophthalmitis?

Answer options

1. Endogenous (bacteraemia or fungaemia). 2. Exogenous (ocular surgery or trauma, extension of corneal infection). 3. Malignant diseases. 4. Idiopatic.

Discussion

Correct Answer: 2. Exogenous (ocular surgery or trauma, extension of corneal infection). Ocular infections due to Moraxella nonliquefaciens have been rarely described. To our knowledge, only eight cases of endophthalmitis due to this microorganism have been previously described in the medical literature [2-7], and here we describe the first case of corneal abscess caused by this pathogen (see Table 1). Most cases of endophthalmitis are exogenous and they are produced as a consequence of ocular surgical procedures, eye traumas or as an extension of corneal infection. Coagulase-negative staphylococci are the most common causes of post-cataract endophthalmitis, and Bacillus cereus is a major cause of post-traumatic endophthalmitis.
Table 1.

Main characteristics of ocular infections due to Moraxella nonliquefaciens

Patient (reference/year of publication) AuthorAge (years)/sexLocalizationUnderlying conditions and/or risk factorsClinical manifestationsMicrobiological diagnosisIdentification methodTreatmentOutcome
1(/1982) Ebright JR62/MEndophthalmosCornea scratched by contact lens Cataract removed three years previously Treatment with prednisone and azathioprine (renal transplant)Scratchy sensation Decrease in visual acuity Injection of the corneaVitreous fluid cultureGenetic transformation assayGentamicin+cephaloridine Penicillin GCure
2(/1985) Lobue TD67/MEndophthalmosTrabeculectomies five years previously Intracapsular cataract extraction in both eyes (six months and one year previously)Tearing and swelling of the right eyelid Decreased visual acuity, pain, hypopyon, pus Corneal microcystic edemaVitreous fluid cultureNRGentamicin+clindamycin CefazolinCure
3(/1985) Lobue TD62/FEndophthalmosBilateral trabeculectomies 15 months previously DMPain, decreased vision, swelling of the eyelid, hypopyon, pusVitreous fluid cultureNRGentamicin+cephaloridine+ cefazolin+tobramycinCure
4(/1993) Sherman MD70/FEndophthalmosCataract extraction and trabeculectomy for lens-induced glaucoma five months previouslyProgressive pain, redness, photophobia, decreased visionVitreous fluid cultureNRCefazolin+tobramycin CefuroximeResidual ischemic damage
5(/1993) Schmidt ME79/MEndophthalmosExtracapsular cataract extraction and trabeculectomy two months previouslyBlurred vision, eye pain, corneal oedema, small hypopyonVitreous fluid cultureBiochemical testsAmikacin+vancomycin+ cefazolin+gentamicin+ceftriaxoneLost of vision
6(/2002) Laukeland H78/MEndophthalmosPrevious trabeculectomy and cataract surgeryPurulent discharge, decreased visual acuity, corneal oedemaAnterior chamber fluid culturePhenotypic characteristics+16S rRNAVancomycin+gentamicin+cefuroximeLost of vision
7(/2002) Laukeland H76/MEndophthalmosCataract surgery and trabeculectomyAcute blurred vision, purulent discharge, corneal oedemaVitreous fluid culturePhenotypic characteristics+16S rRNAVancomycin+gentamicin+cefuroximeLost of vision
8(PR/2017) Cobo F71/MCorneaCorneal damageRed eye, loss of vision, corneal oedemaCorneal abscess cultureMaldi-tof MSVancomycin+ceftazidime+tobramycin AzythromycinImproved

M: male; F: female; DM: diabetes mellitus; NR: not reported; CRP: C-reactive protein; PR: present report.

The case of Mandelbaum et al. [3] did not show sufficient data to be included in the table.

M: male; F: female; DM: diabetes mellitus; NR: not reported; CRP: C-reactive protein; PR: present report. The case of Mandelbaum et al. [3] did not show sufficient data to be included in the table. Ocular infections, such as corneal abscesses and endophthalmitis, are a medical emergency. Treatment of corneal traumas is very important in order to avoid dissemination of infection into the eye. Prompt and appropriate treatment of these lesions may help to both avoid complications and recover total vision.
  6 in total

1.  Posttrabeculectomy endophthalmitis caused by Moraxella nonliquefaciens.

Authors:  Helene Laukeland; Kåre Bergh; Lars Bevanger
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

2.  Endophthalmitis caused by beta-lactamase-positive Moraxella nonliquefaciens.

Authors:  M D Sherman; M York; A R Irvine; P Langer; V Cevallos; J P Whitcher
Journal:  Am J Ophthalmol       Date:  1993-05-15       Impact factor: 5.258

3.  Late onset endophthalmitis associated with filtering blebs.

Authors:  S Mandelbaum; R K Forster; H Gelender; W Culbertson
Journal:  Ophthalmology       Date:  1985-07       Impact factor: 12.079

4.  Moraxella nonliquefaciens endophthalmitis after trabeculectomy.

Authors:  T D Lobue; T A Deutsch; R M Stein
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

Review 5.  Endophthalmitis caused by unusual gram-negative bacilli: three case reports and review.

Authors:  M E Schmidt; M A Smith; C S Levy
Journal:  Clin Infect Dis       Date:  1993-10       Impact factor: 9.079

6.  Endophthalmitis caused by Moraxella nonliquefaciens.

Authors:  J R Ebright; J R Lentino; E Juni
Journal:  Am J Clin Pathol       Date:  1982-03       Impact factor: 2.493

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.